Fabian Schmidt

HIV-1-induced AIDS in monkeys.

Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host.

Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State.

Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection.

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.

Convergent antibody responses to SARS-CoV-2 in convalescent individuals.

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients.

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection .

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.

Evolution of antibody immunity to SARS-CoV-2.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies.

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2.

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity.

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.

Replication and single-cycle delivery of SARS-CoV-2 replicons.

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.

Plasma neutralization properties of the SARS-CoV-2 Omicron variant.

Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins.

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost.

Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis.

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection.

Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection.

Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination.

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.

Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans.

Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination.

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.